| Secondary |
| Drug Use For Unknown Indication |
15.7% |
| Infection |
9.3% |
| Arthritis Bacterial |
8.0% |
| Osteomyelitis |
7.8% |
| Staphylococcal Infection |
5.8% |
| Hypertension |
5.5% |
| Diabetes Mellitus |
5.1% |
| Viral Infection |
5.1% |
| Hiv Infection |
4.9% |
| Sinus Disorder |
4.4% |
| Osteitis |
4.0% |
| Localised Infection |
3.5% |
| Deformity Thorax |
3.3% |
| Hypercholesterolaemia |
3.3% |
| Erythrosis |
3.1% |
| Product Used For Unknown Indication |
2.9% |
| Myocardial Ischaemia |
2.2% |
| Wound Infection |
2.2% |
| Constipation |
2.0% |
| Bacterial Infection |
1.8% |
|
| Rhabdomyolysis |
42.0% |
| Renal Failure Acute |
7.6% |
| Jaundice |
6.9% |
| Agranulocytosis |
4.6% |
| Drug Interaction |
3.8% |
| Thrombocytopenia |
3.8% |
| Toxic Epidermal Necrolysis |
3.8% |
| White Blood Cell Count Increased |
3.8% |
| Pancytopenia |
3.1% |
| Toxic Skin Eruption |
3.1% |
| Hyperbilirubinaemia |
2.3% |
| Renal Failure |
2.3% |
| Vascular Purpura |
2.3% |
| Catheter Site Phlebitis |
1.5% |
| Drug Rash With Eosinophilia And Systemic Symptoms |
1.5% |
| Dysphagia |
1.5% |
| Eosinophil Count Increased |
1.5% |
| Eosinophilia |
1.5% |
| Hepatitis Cholestatic |
1.5% |
| Jaundice Cholestatic |
1.5% |
|
| Concomitant |
| Product Used For Unknown Indication |
19.8% |
| Drug Use For Unknown Indication |
15.6% |
| Prophylaxis |
12.8% |
| Hypertension |
7.3% |
| Hiv Infection |
6.9% |
| Pain |
4.1% |
| Depression |
3.8% |
| Rash |
2.9% |
| Hypercholesterolaemia |
2.7% |
| Angina Pectoris |
2.6% |
| Staphylococcal Infection |
2.6% |
| Constipation |
2.4% |
| Non-small Cell Lung Cancer |
2.4% |
| Breast Cancer |
2.2% |
| Diabetes Mellitus |
2.2% |
| Insomnia |
2.2% |
| Diarrhoea |
2.1% |
| Angiosarcoma Metastatic |
1.9% |
| Mitochondrial Toxicity |
1.9% |
| Asthma |
1.6% |
|
| Toxic Epidermal Necrolysis |
11.3% |
| Multi-organ Failure |
7.5% |
| Deep Vein Thrombosis |
6.3% |
| Rhabdomyolysis |
6.3% |
| Ruptured Cerebral Aneurysm |
6.3% |
| Dehydration |
5.0% |
| Renal Failure Acute |
5.0% |
| Sepsis |
5.0% |
| Squamous Cell Carcinoma |
5.0% |
| Vomiting |
5.0% |
| Anaemia |
3.8% |
| Anaphylactic Reaction |
3.8% |
| Cytolytic Hepatitis |
3.8% |
| Dizziness |
3.8% |
| Furuncle |
3.8% |
| Nail Bed Inflammation |
3.8% |
| Pancreatic Insufficiency |
3.8% |
| Pyrexia |
3.8% |
| Salivary Hypersecretion |
3.8% |
| Thrombocytopenia |
3.8% |
|
| Interacting |
| Cardiac Failure |
10.1% |
| Hypercholesterolaemia |
8.0% |
| Osteitis |
7.2% |
| Osteomyelitis |
7.2% |
| Depression |
5.8% |
| Infection |
5.8% |
| Product Used For Unknown Indication |
5.8% |
| Cardiac Infection |
5.1% |
| Conduction Disorder |
5.1% |
| Drug Use For Unknown Indication |
5.1% |
| Localised Infection |
5.1% |
| Hypertension |
4.3% |
| Myocardial Ischaemia |
4.3% |
| Rheumatoid Arthritis |
4.3% |
| Wound Infection |
4.3% |
| Device Related Infection |
2.9% |
| Type 2 Diabetes Mellitus |
2.9% |
| Acute Coronary Syndrome |
2.2% |
| Diabetic Foot Infection |
2.2% |
| Dyslipidaemia |
2.2% |
|
| Rhabdomyolysis |
61.5% |
| Alanine Aminotransferase Increased |
5.1% |
| Drug Interaction |
5.1% |
| Renal Failure Acute |
5.1% |
| Blood Creatine Phosphokinase Increased |
2.6% |
| Cytolytic Hepatitis |
2.6% |
| Drug Administration Error |
2.6% |
| Grand Mal Convulsion |
2.6% |
| Myalgia |
2.6% |
| Nausea |
2.6% |
| Oedema Peripheral |
2.6% |
| Speech Disorder |
2.6% |
| Staphylococcal Infection |
2.6% |
|
